Cite
HARVARD Citation
Hartinger, J. et al. (2019). Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. European journal of hospital pharmacy. 26 (4), pp. 210-213. [Online].